New stool tests for colorectal cancer screening: A systematic review focusing on performance characteristics and practicalness

International Journal of Cancer

Volumn 117, Issue 2, 2005, Pages 169-176

  Haug, Ulrike ^a   Brenner, Hermann ^a  

^a GERMAN CENTRE FOR RESEARCH ON AGEING   (Germany)

Author keywords

Colorectal cancer; Stool test

Indexed keywords

APC PROTEIN; CALPROTECTIN; CARCINOEMBRYONIC ANTIGEN; DECAY ACCELERATING FACTOR; DEOXYCHOLIC ACID; DNA; HERMES ANTIGEN; K RAS PROTEIN; LYSOZYME; MINICHROMOSOME MAINTENANCE PROTEIN 2; MUCIN; PROTEIN P53; PYRUVATE KINASE; TUMOR MARKER;

AGE; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; DEFECATION; DNA METHYLATION; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HUMAN; MASS SCREENING; MEDLINE; META ANALYSIS; MICROSATELLITE INSTABILITY; OCCULT BLOOD; ONCOGENE K RAS; PRIORITY JOURNAL; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

ADENOMA; COLORECTAL NEOPLASMS; FECES; HUMANS; MASS SCREENING; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 25444447776     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21016     Document Type: Short Survey

References (39)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base 5. Lyon: IARC, 2001, http://www-dep.iarc.fr/globocan/ globocan.html.
2. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7.
3. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
4. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
5. Ratto C, Flamini G, Sofo L, Nucera P, Ippoliti M, Curigliano G, Ferretti G, Sgambato A, Merico M, Doglietto GB, Cittadini A, Crucitti F. Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum 1996;39:1238-44.
6. Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, Losi L, Perini M, Trande P, Merighi A, Lerose R, Manenti F. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996;110: 1346-53.
7. Puig P, Urgell E, Capella G, Sancho FJ, Pujol J, Boadas J, Farre A, Lluis F, Gonzalez-Sastre F, Mora J. A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer. Int J Cancer 2000;85:73-7.
8. Wan J, Zhang ZQ, You WD, Sun HK, Zhang JP, Wang YH, Fu YH. Detection of K-ras gene mutation in fecal samples from elderly large intestinal cancer patients and its diagnostic significance. World J Gastroenterol 2004;10:743-6.
9. Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ Jr, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
10. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002;359:403-4.
11. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, Muhlthaler M, Ofner D, Margreiter R, Widschwendter M. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-5.
12. Loktionov A, O'Neill IK, Silvester KR, Cummings JH, Middleton SJ, Miller R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998;4:337-42.
13. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49:1058-65.
14. Koshiji M, Yonekura Y, Saito T, Yoshioka K. Microsatellite analysis of fecal DNA for colorectal cancer detection. J Surg Oncol 2002;80: 34-40.
15. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
16. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003;1:377-83.
17. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003;3:47-53.
18. Dubrow R, Kim CS, Eldred AK. Fecal lysozyme: an unreliable marker for colorectal cancer. Am J Gastroenterol 1992;87:617-21.
19. Mizuno M, Nakagawa M, Uesu T, Inoue H, Inaba T, Ueki T, Nasu J, Okada H, Fujita T, Tsuji T. Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer. Gastroenterology 1995;109:826-31.
20. Mizuno M, Mizuno M, Iwagaki N, Nasu J, Okazaki H, Yamamoto K, Okada H, Tsuji T, Fujita T, Shiratori Y. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer. Am J Gastroenterol 2003;98:2550-5.
21. Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, Roald B. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
22. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott K, Moshakis V, Reynolds JR. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000; 46:795-800.
23. Johne B, Kronborg O, Ton HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-6.
24. Kristinsson J, Nygaard K, Aadland E, Barstad S, Sauar J, Hofstad B, Stray N, Stallemo A, Haug B, Ugstad M, Ton H, Fuglerud P. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion 2001;64:104-10.
25. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402-8.
26. Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003; 98:2299-305.
27. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004;53:1329-33.
28. Kim Y, Lee S, Park S, Jeon H, Lee W, Kim JK, Cho M, Kim M, Lim J, Kang CS, Han K. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci 2003;33:32-8.
29. Yamao T, Matsumura Y, Shimada Y, Moriya Y, Sugihara K, Akasu T, Fujita S, Kakizoe T. Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology 1998;114:1196-205.
30. Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, Laskey RA, Miller R, Coleman N. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002;359:1917-9.
31. Pant KD, McCracken JD. Noninvasive colorectal cancer screening. Dig Dis Sci 2002;47:1236-40.
32. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004;91:980-4.
33. Kamano T, Mikami Y, Kurasawa T, Tsurumaru M, Matsumoto M, Kano M, Motegi K. Ratio of primary and secondary bile acids in feces: possible marker for colorectal cancer? Dis Colon Rectum 1999; 42:668-72.
34. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test: a background paper. Ann Intern Med 1997; 126:811-22.
35. Summerton C, Longlands M, Wiener K, Shreeve D. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:841-5.
36. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004;126:1270-9.
37. Exact Sciences. Corporation press release, October 11, 2003. PreGen-Plus four times more sensitive than FOBT in Exact Sciences' multicenter study, http://www.exactsciences.com (accessed June 30, 2004).
38. Frattini M, Balestra D, Pilotti S, Bertario L, Pierotti MA. Tumor location and detection of k-ras mutations in stool from colorectal cancer patients. J Natl Cancer Inst 2003;95:72-3.
39. Boland CR. Molecular basis for stool-based DNA tests for colorectal cancer: a primer for clinicians. Rev Gastroenterol Disord. 2002; 2(Suppl 1):12-19.